Yiran Gan 4/5/25 Yiran Gan 4/5/25 Clinical Feasibility of Biofunctionalized Magnetic Nanoparticles for Detecting Multiple Cardiac Biomarkers in Emergency Chest Pain Patients Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Using Immunomagnetic Reduction to Assay Reagent Stability of Biomarkers Associated with Alzheimer's Disease Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Neurofilament light chain level in plasma extracellular vesicles and Parkinson’s disease Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Development of Assaying Plasma TDP-43 Utilizing Immunomagnetic Reduction Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model Read More Yiran Gan 4/5/25 Yiran Gan 4/5/25 Plasma Biomarkers Ascertained with Immunomagnetic Reduction Diagnosing Early-Stage Alzheimer's Disease: A Systematic Review Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease Read More Yiran Gan 4/4/25 Yiran Gan 4/4/25 The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease Read More Newer Posts Older Posts
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Clinical Feasibility of Biofunctionalized Magnetic Nanoparticles for Detecting Multiple Cardiac Biomarkers in Emergency Chest Pain Patients Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Synergistic Association between Plasma Aβ1–42 and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Using Immunomagnetic Reduction to Assay Reagent Stability of Biomarkers Associated with Alzheimer's Disease Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Neurofilament light chain level in plasma extracellular vesicles and Parkinson’s disease Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Development of Assaying Plasma TDP-43 Utilizing Immunomagnetic Reduction Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model Read More
Yiran Gan 4/5/25 Yiran Gan 4/5/25 Plasma Biomarkers Ascertained with Immunomagnetic Reduction Diagnosing Early-Stage Alzheimer's Disease: A Systematic Review Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease Read More
Yiran Gan 4/4/25 Yiran Gan 4/4/25 The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease Read More
